EIF2AK4 and melanoma: Although GCN2 expression has not been documented so far to be increased in any malignancy, PKR levels and/or activity have been reported to be elevated in breast cancer [35], melanoma and colon cancer cell lines [36] and hematological malignancies [37], raising the possibility that these cancers might be good candidates for treatment with these agents.